Compile Data Set for Download or QSAR
Report error Found 10716 Enz. Inhib. hit(s) with Target = 'Plasma kallikrein'
TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283363(US10023557, Example 15 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283364(US10023557, Example 16 | N-((1-aminoisoquinolin-6-...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283365(US10023557, Example 17 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283366(US10023557, Example 18 | N-((6-fluoro-1H-indol-5-y...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283368(US10023557, Example 20 | N-((5-chloro-1H-indazol-3...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283369(US10023557, Example 21 | N-((3-chloro-4-fluoro-1H-...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283379(N-((1-aminoisoquinolin-6-yl)methyl)-2-((3- chloroq...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283381(US10023557, Example 33 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283383(US10023557, Example 35 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283386(US10023557, Example 38 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283388(US10023557, Example 40 | N-((3-chloro-4-fluoro-1H-...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283398(US10023557, Example 50 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283404(US10023557, Example 56 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283405(US10023557, Example 57 | N-((1-aminoisoquinolin-6-...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283406(US10023557, Example 58 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283407(US10023557, Example 59 | 3-chloro-6-((4-(((3-chlor...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283408(US10023557, Example 60 | 3-chloro-6-((4-(((5-chlor...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283409(US10023557, Example 61 | 3-chloro-6-((4-(((3-chlor...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283410(US10023557, Example 62 | 6-((4-(((6-amino-2-methyl...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283412(US10023557, Example 64 | 6-((4-(((1-aminoisoquinol...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283413(US10023557, Example 65 | 3-chloro-6-((4-(((3-chlor...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283414(US10023557, Example 66 | 3-chloro-6-((4-(((6-fluor...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283415(US10023557, Example 67 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283416(US10023557, Example 68 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283417(US10023557, Example 69 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283418(US10023557, Example 70 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283419(US10023557, Example 71 | N-((1-aminoisoquinolin-6-...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283420(US10023557, Example 72 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283421(US10023557, Example 73 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283425(US10023557, Example 77 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283426(US10023557, Example 78 | 6-((4-(((3-chloro-6-fluor...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283427(US10023557, Example 79 | 6-((4-(((1-aminoisoquinol...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283428(US10023557, Example 80 | 6-((4-(((3-chloro-1H-pyrr...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283429(US10023557, Example 81 | 6-((4-(((3-chloro-4-fluor...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283430(US10023557, Example 82 | 6-((4-(((5-chloro-1H-inda...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283431(US10023557, Example 83 | 6-((4-(((6-fluoro-1H-indo...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283432(US10023557, Example 84 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283437(US10023557, Example 89 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283439(US10023557, Example 91 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283440(US10023557, Example 92 | methyl 6-((4-(((6-amino-2...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283441(US10023557, Example 93 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283445(US10023557, Example 97 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283447(US10023557, Example 99 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283448(US10023557, Example 100 | N-((6-amino-2,4-dimethyl...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283449(US10023557, Example 101 | N-((6-amino-2-methylpyri...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283450(US10023557, Example 102 | N-((6-amino-2,4-dimethyl...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283452(N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)- 2-((...)
Affinity DataEC50: <100nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283458(US10023557, Example 110 | N-((3-chloro-6-fluoro-1H...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283459(US10023557, Example 111 | N-((1-aminoisoquinolin-6...)
Affinity DataEC50:  550nMAssay Description:The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
US Patent

Displayed 1 to 50 (of 10716 total ) | Next | Last >>
Jump to: